{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:30:06Z","timestamp":1781299806765,"version":"3.54.1"},"update-to":[{"DOI":"10.12688\/f1000research.149172.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000}}],"reference-count":30,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns3:p>\n                    Background Psoriasis, a chronic inflammatory disease affecting the skin, joints, and nails (2-3% worldwide), significantly affects quality of life. Genetic and environmental factors also play key roles. Topical corticosteroids, calcineurin inhibitors, and oral corticosteroids help to manage plaque psoriasis symptoms, but combination therapies might offer greater effectiveness and improved safety profiles. These combinations could potentially reduce medication dosages and side effects in patients. Objective To assess the efficacy and safety of various drug combinations over conventional monotherapies in the treatment of moderate to severe plaque psoriasis, which incorporates palmoplantar psoriasis and psoriasis vulgaris, by discovering and utilizing research articles comprising the same or similar variables as PASI 75 and evaluating the information using RevMan v5.4.1. Method We reviewed the efficacy and safety of combination therapy vs. monotherapy\/placebo for moderate-to-severe plaque psoriasis (palmoplantar and vulgaris) using PASI 75 via RevMan v5.4.1. Risk of bias assessment and funnel plots were employed to assess the heterogeneity of each paper. Inclusion criteria \u2013 Publications &lt; 20yrs, RCTs, plaque\/palmoplantar\/psoriasis vulgaris; exclusion criteria \u2013 Guttate\/arthritic psoriasis, pediatric and pregnant individuals, publications &gt; 20 yrs. Results Seventeen studies were analyzed, comprising a total of 2291 patients (n=1147 with combination regimens and n=1144 with control regimen in the analysis). A significant PASI 75- response was observed in the pioglitazone combination subgroup as compared to placebo (OR=4.92,95% CI 2.19-11.05, P = 0.0001); methotrexate combination subgroup as compared to placebo (OR=2.56, 95% CI 1.67-3.94, P&lt; 0.0001) test of subgroup differences showed P= 0.14, I\n                    <ns3:sup>2<\/ns3:sup>\n                    = 34%. Incidence rate of abnormality in levels of liver enzymes (OR=1.89,9.5% CI 6.69-5.22, P=0.22), nausea (OR=1.28,95% CI 0.77-2.14, P=0.34), headache (OR=1.28,95% CI 0.77-2.14, P=0.58), fatigue (OR=0.89, 95% CI 0.41-1.90, P=0.45).] Conclusion This study showed that combination therapy is very effective for plaque psoriasis, with promising combinations of pioglitazone. While safety seems similar between the groups, larger studies are needed to determine the long-term effects. These findings suggest that personalized treatment plans could improve outcomes; however, confirmation through larger trials is crucial before wider use. This opens doors to research on optimal combinations for individual patients.\n                  <\/ns3:p>","DOI":"10.12688\/f1000research.149172.2","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T08:25:11Z","timestamp":1738052711000},"page":"453","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of various drug combinations in treating plaque Psoriasis: A meta-analysis"],"prefix":"10.12688","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5955-7890","authenticated-orcid":false,"given":"Nayak","family":"Snehasis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1299-3307","authenticated-orcid":false,"given":"Sayed","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2572-1800","authenticated-orcid":false,"given":"Ngabo","family":"Herve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1107-1166","authenticated-orcid":false,"given":"Pendyala","family":"Siri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1169-0115","authenticated-orcid":false,"given":"Karshe","family":"Haji Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"680-686","DOI":"10.1080\/09546634.2019.1610552","article-title":"Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.","volume":"31","author":"G Chang","year":"2020 Oct 2","journal-title":"J. Dermatolog. Treat."},{"key":"ref2","article-title":"ADVANCING PSORIASIS TREATMENT Clinical drug evaluation of fumaric acid esters and TLR-antagonists.","author":"D Balak","year":"2018"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"16-22","DOI":"10.4103\/ijp. IJP_88_19","article-title":"The evaluation of efficacy and safety of methotrexate and pioglitazone in psoriasis patients: A randomized, open-labeled, active-controlled clinical trial.","volume":"52","author":"A Abidi","year":"2020 Jan","journal-title":"Indian J. Pharm."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1345-1349","DOI":"10.1111\/j.1365-2133.2008.08564.x","article-title":"Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: A 24-week, randomized, controlled, investigator-blinded pilot trial.","volume":"158","author":"P Gisondi","year":"2008 Jun","journal-title":"Br. J. Dermatol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"213-220","DOI":"10.25259\/IJDVL_843_2021","article-title":"Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessor-blinded, comparative study.","volume":"89","author":"T Hassanandani","year":"2022","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref6","doi-asserted-by":"crossref","article-title":"The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial.","author":"V Lajevardi","DOI":"10.1111\/ijd.12585"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"664-667","DOI":"10.1080\/09546634.2018.1544702","article-title":"Efficacy and safety of pioglitazone plus phototherapy versus phototherapy in patients with plaque type psoriasis: a Double Blinded Randomized Controlled Trial.","volume":"30","author":"M Ghiasi","year":"2019","journal-title":"J. Dermatolog. Treat."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"649-657","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.","volume":"167","author":"A Gottlieb","year":"2012 Sep","journal-title":"Br. J. Dermatol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1001\/archdermatol.2011.1916","article-title":"Combination Treatments for Psoriasis.","volume":"148","author":"E Ference","year":"2012 Apr","journal-title":"Arch. Dermatol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"255-260","DOI":"10.3109\/09546634.2011.565017","article-title":"Combined treatment with low-dose cyclosporine and calcipotriol\/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: A randomized controlled open-label study.","volume":"23","author":"G Vena","year":"2012 Aug","journal-title":"J. Dermatolog. Treat."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"595-600","DOI":"10.1111\/j.1468-3083.2009.03486.x","article-title":"Methotrexate\/narrowband UVB phototherapy combination vs. narrowband UVB phototherapy in the treatment of chronic plaque-type psoriasis - A randomized single-blinded placebo-controlled study.","volume":"24","author":"R Mahajan","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"214-222","DOI":"10.25259\/IJDVL_613_19","article-title":"Safety and efficacy of methotrexate (0.3 mg\/kg\/week) versus a combination of methotrexate (0.15 mg\/kg\/week) with cyclosporine (2.5 mg\/kg\/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.","volume":"87","author":"S Singh","year":"2021 Mar","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"341-349","DOI":"10.2340\/00015555-0905","article-title":"Systemic Combination Treatment for Psoriasis: A Review.","volume":"90","author":"P Jensen","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"9-25","DOI":"10.1007\/s40257-012-0003-7","article-title":"Combination Therapy in Psoriasis.","volume":"14","author":"C Gustafson","year":"2013 Feb","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1211-1220","DOI":"10.1111\/1346-8138.16566","article-title":"Efficacy and safety of apremilast and phototherapy versus phototherapy only in psoriasis vulgaris.","volume":"49","author":"A Morita","year":"2022 Dec","journal-title":"J. Dermatol."},{"key":"ref16","article-title":"Evaluation of Role of Add on Anti Hyperglycaemic Drugs Metformin and Pioglitazone in Patients of Psoriasis with Metabolic Syndrome.","author":"M Gupta","year":"2020"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.3310\/hta15100","article-title":"Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.","author":"M Rodgers","year":"2011"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"287-293","DOI":"10.1016\/j.jaad.2018.03.040","article-title":"Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.","volume":"79","author":"L Gold","year":"2018 Feb","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","author":"J Higgins","year":"2003"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"437-445","DOI":"10.1007\/s00403-019-02024-6","article-title":"Etanercept biosimilar (recombinant human tumor necrosis factor-\u03b1 receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.","volume":"312","author":"L Liu","year":"2020 Aug","journal-title":"Arch. Dermatol. Res."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1001\/jamadermatol.2014.1111","article-title":"Combined Use of Systemic Agents for Psoriasis.","volume":"150","author":"C Busard","year":"2014 Nov","journal-title":"JAMA Dermatol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"385-392","DOI":"10.1016\/j.jaad.2013.03.031","article-title":"A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.","volume":"69","author":"M Lebwohl","year":"2013 Sep","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"680-686","DOI":"10.1080\/09546634.2019.1610552","article-title":"Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.","volume":"31","author":"G Chang","year":"2020 Oct 2","journal-title":"J. Dermatolog. Treat."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12895-016-0049-y","article-title":"Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort).","volume":"16","author":"S Singh","year":"2016 Aug","journal-title":"BMC Dermatol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"316-323","DOI":"10.1046\/j.1365-2133.2002.04967.x","article-title":"Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.","volume":"147","author":"L Guenther","year":"2002 Aug","journal-title":"Br. J. Dermatol."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25656471.v1","article-title":"Efficacy and safety of various drug combinations of various drug combinations in treating plaque psoriasis: A meta analysis - Figures(Forest plots, flowcharts, RoB2).","author":"S Nayak","year":"2024 cited 2024Apr20","journal-title":"figshare."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25656465.v1","article-title":"String operations employed in Efficacy and safety of various drug combinations in treating plaque psoriasis: A meta analysis.","author":"S Nayak","year":"2024 cited 2024 Apr 20","journal-title":"figshare."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25656411.v2","article-title":"Risk of bias excel tool with MACROS for included studies in \u2018Efficacy and safety of various drug combinations in treating plaque psoriasis: A meta analysis\u2019.","author":"S Nayak","year":"024 cited 2024 Apr 24","journal-title":"figshare."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25656405.v2","article-title":"intervalidation META ANALYSIS.xlsx.","author":"S Nayak","year":"2024 cited 2024 Apr 24","journal-title":"figshare."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.25656444.v3","article-title":"PRISMA CHECKLIST v2020 for \u2018Efficacy and safety of various drug combinations in treating plaque psoriasis: A meta analysis\u2019.","author":"S Nayak","year":"2024 cited 2024 Apr 24","journal-title":"figshare."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/13-453\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-453\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/13-453\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T04:50:15Z","timestamp":1738817415000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/13-453\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":30,"URL":"https:\/\/doi.org\/10.12688\/f1000research.149172.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/f1000research.149172.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.177366.r363099","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.177366.r363099","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/13-453\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.177366.r363099, Naoko Kanda, Nippon Medical School Chiba Hokusoh Hospital, Inzai, 06 Feb 2025, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/13-453\/v2#referee-response-363099","order":0,"name":"referee-response-363099","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.163592.r281705, Romana \u010ceovi\u0107, University of Zagreb, Zagreb, 17 Jun 2024, version 1, 1 approved, 1 not approved","URL":"https:\/\/f1000research.com\/articles\/13-453\/v1#referee-response-281705","order":1,"name":"referee-response-281705","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}